Clinical Investigators Advocate for Evolving Lupus Nephritis Clinical Trial Design (ACR Convergence 2026) - Sep 8, 2026 - Abstract #517; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Randomized clinical trials published since 2010 typically used control arms of placebo plus either mycophenolic acid analog (MPAA) or cyclophosphamide (CYC), including those leading to the FDA approval of voclosporin, belimumab (BEL), and obinutuzumab...Additionally, LN trial protocols have required prolonged washout periods up to 12 months for anti-CD20 (e.g. rituximab) or 12 weeks for other prohibited concomitant therapies, creating tension between optimizing the care of active disease and avoiding progression of renal damage in patients waiting to qualify for trials... SLE patients with LN represent a high-risk population requiring prompt and effective treatment to reduce morbidity and mortality. Investigators with experience in lupus nephritis trials generally regarded prolonged prohibited therapy washout periods and the prior standard of mycophenolate plus glucocorticoid control arms as misaligned with current clinical practice. These findings provide a..."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Cristina Arriens1; Yashaar Chaichian2; Jose Rubio3; Meenakshi Jolly4; Emily Lewis5; Abraham Sinay-Smith6; Brandon Jackson7
|